K.-W. Lee

606 total citations · 1 hit paper
16 papers, 378 citations indexed

About

K.-W. Lee is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, K.-W. Lee has authored 16 papers receiving a total of 378 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in K.-W. Lee's work include Gastric Cancer Management and Outcomes (9 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers). K.-W. Lee is often cited by papers focused on Gastric Cancer Management and Outcomes (9 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers). K.-W. Lee collaborates with scholars based in South Korea, Japan and United States. K.-W. Lee's co-authors include Yoon‐Koo Kang, Min‐Hee Ryu, Narikazu Boku, Ken Kato, Hyun Cheol Chung, Hiroki Hara, Mizutomo Azuma, Keiko Minashi, Kensei Yamaguchi and Won Ki Kang and has published in prestigious journals such as Annals of Oncology, Japanese Journal of Clinical Oncology and PubMed.

In The Last Decade

K.-W. Lee

16 papers receiving 374 citations

Hit Papers

Safety and efficacy of nivolumab in combination with S-1/... 2018 2026 2020 2023 2018 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
    2018 228 citations Narikazu Boku, Min‐Hee Ryu et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K.-W. Lee South Korea 7 252 242 131 121 37 16 378
Markus Moehler Germany 9 207 0.8× 175 0.7× 126 1.0× 46 0.4× 45 1.2× 24 320
T. Pudlarz France 9 244 1.0× 244 1.0× 156 1.2× 88 0.7× 34 0.9× 26 416
Udo Lindig Germany 10 181 0.7× 210 0.9× 134 1.0× 83 0.7× 19 0.5× 36 298
Syoichi Fujii Japan 8 203 0.8× 280 1.2× 195 1.5× 102 0.8× 12 0.3× 12 446
Tong Xie China 10 228 0.9× 189 0.8× 81 0.6× 41 0.3× 52 1.4× 24 350
Arinilda Campos Bragagnoli Brazil 6 159 0.6× 131 0.5× 94 0.7× 44 0.4× 21 0.6× 15 244
Sejung Park South Korea 10 155 0.6× 151 0.6× 120 0.9× 40 0.3× 20 0.5× 22 274
Jian-Xian Lin China 11 107 0.4× 211 0.9× 151 1.2× 102 0.8× 35 0.9× 47 385
Yuriy Ostapenko Ukraine 3 131 0.5× 149 0.6× 73 0.6× 62 0.5× 25 0.7× 6 227
Seung Tae Kim South Korea 9 186 0.7× 169 0.7× 89 0.7× 43 0.4× 53 1.4× 16 322

Countries citing papers authored by K.-W. Lee

Since Specialization
Citations

This map shows the geographic impact of K.-W. Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.-W. Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.-W. Lee more than expected).

Fields of papers citing papers by K.-W. Lee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.-W. Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.-W. Lee. The network helps show where K.-W. Lee may publish in the future.

Co-authorship network of co-authors of K.-W. Lee

This figure shows the co-authorship network connecting the top 25 collaborators of K.-W. Lee. A scholar is included among the top collaborators of K.-W. Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.-W. Lee. K.-W. Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Klempner, Samuel J., Roberto Pazo-Cid, Sara Lonardi, et al.. (2025). Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study. PubMed. 7. 100131–100131. 4 indexed citations
2.
3.
Oh, Do‐Youn, Erika Hamilton, Diana L. Hanna, et al.. (2019). Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours. Annals of Oncology. 30. ix22–ix22. 9 indexed citations
4.
Chung, Hyun Cheol, Yung‐Jue Bang, Josep Tabernero, et al.. (2019). Pembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study. Annals of Oncology. 30. ix43–ix44. 3 indexed citations
5.
Lee, K.-W., In Sil Choi, & Jae Hyoung Kim. (2018). A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study. Annals of Oncology. 29. ix51–ix52. 1 indexed citations
6.
Boku, Narikazu, Min‐Hee Ryu, Ken Kato, et al.. (2018). Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Annals of Oncology. 30(2). 250–258. 228 indexed citations breakdown →
7.
8.
Beom, Seung‐Hoon, K.-W. Lee, Y.S. Park, et al.. (2018). A phase II study of pemetrexed and erlotinib for metastatic colorectal cancer refractory to standard chemotherapy. Annals of Oncology. 29. viii190–viii190. 1 indexed citations
9.
Lee, K.-W., Byung Woog Kang, Ick‐Joong Chung, et al.. (2018). Treatment patterns and changes in quality of life during first-line palliative chemotherapy in Korean patients with advanced gastric cancer. Annals of Oncology. 29. viii228–viii228. 5 indexed citations
10.
Catenacci, Daniel V.T., Hope E. Uronis, Yoon‐Koo Kang, et al.. (2018). Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA). Annals of Oncology. 29. viii223–viii223. 3 indexed citations
11.
Satoh, Taroh, L.-T. Chen, Yoon‐Koo Kang, et al.. (2018). A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data. Annals of Oncology. 29. viii206–viii206. 9 indexed citations
12.
Patel, Manish R., John Ellerton, Manish Agrawal, et al.. (2016). Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible. Annals of Oncology. 27. vi267–vi267. 18 indexed citations
13.
Lee, Ki Hoon, Do‐Youn Oh, K.-W. Lee, et al.. (2012). A Phase II Open Label Trial of PF-00299804 Monotherapy in Patients with HER-2 Positive Advanced Gastric Cancer After Failure of at Least one Prior Chemotherapy Regimen. Annals of Oncology. 23. xi19–xi20. 1 indexed citations
14.
Chang, Hye Jung, K.-W. Lee, Jee Hyun Kim, et al.. (2011). Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer. Annals of Oncology. 23(4). 911–918. 19 indexed citations
15.
Beom, Seung‐Hoon, K.-W. Lee, Ye Yang, et al.. (2011). Metastatic Adrenocortical Carcinoma Presenting Simultaneously with Cushing's and Conn's Syndromes: A Case Report. Japanese Journal of Clinical Oncology. 41(11). 1287–1291. 3 indexed citations
16.
Seo, Min‐Duk, K.-W. Lee, Hyeon Gyu Yi, et al.. (2008). Irinotecan Combined with 5-Fluorouracil and Leucovorin as Second-line Chemotherapy for Metastatic or Relapsed Gastric Cancer. Japanese Journal of Clinical Oncology. 38(9). 589–595. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Markus Moehler Breakdown of academic impact, for papers by T. Pudlarz Breakdown of academic impact, for papers by Udo Lindig Breakdown of academic impact, for papers by Syoichi Fujii Breakdown of academic impact, for papers by Tong Xie Breakdown of academic impact, for papers by Arinilda Campos Bragagnoli Breakdown of academic impact, for papers by Sejung Park Breakdown of academic impact, for papers by Jian-Xian Lin Breakdown of academic impact, for papers by Yuriy Ostapenko Breakdown of academic impact, for papers by Seung Tae Kim
Rankless by CCL
2026